The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In this SOHO Insider interview from the 2026 AACR Annual Meeting, Roy Jensen, MD, vice chancellor and director of the University of Kansas Cancer Center (KU Cancer Center), discusses point-of-care CAR-T manufacturing and the regulatory challenges associated with the process.
In vivo CAR-T therapy, which eliminates the complex manufacturing required for current ex vivo approaches, could represent the next generation of treatment, but early data raise safety concerns, including inflammatory toxicity, according to a presentation by Saar Gill, MD, PhD, an associate professor of medicine, at the University of Pennsylvania.
In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin,
The phase 3 trial evaluated the safety and efficacy of odronextamab, a CD20xCD3 bispecific antibody, in combination with CHOP chemotherapy for patients with untreated DLBCL.
The phase 3 inMIND trial evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide in adult patients with relapsed or refractory follicular lymphoma. The trial showed that the treatment reached its primary endpoint and that the treatment was well tolerated, with a manageable safety profile.
To access the SOHO Career Center click the following link.
